| 摘要 |
A method for the treatment of cancer, comprising the administration to a mammal in need thereof a synergistic, therapeutically effective amount of (i) an anti-CTLA-4 antibody, in addition to one or more diluents, vehicles, excipients, and/or inactive ingredients, and (ii) N (2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)- 1 -piperazinyl]-2-methyl-4pyrimidinyl] amino] -5-thiazolecarboxamide (dasatinib), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in addition to one or more diluents, vehicles, excipients, and/or inactive ingredients. |
